Publications of Udo Reichl

Göbel, S.; Legmann, R.; Altomonte, J.; Kamen, A.; Reichl, U.; Genzel, Y.: Intensified production of a fusogenic oncolytic virus by tangential flow depth filtration. Levitronix Bioprocessing Conference, Cambridge (USA) (2024)

Göbel, S.; Pineda, E.; Keebler, M.; Reichl, U.; Genzel, Y.; Lehrer, A.: Process optimization for recombinant Marburg virus glycoprotein production using Drosophila S2 cells. Vaccine Technology IX, Cabo San Lucas (Mexico) (2024)

Pelz, L.; Rüdiger, D.; Hein, M.; Böhme, J.; Bälkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A.; Genzel, Y.; Bruder, D. et al.; Kupke, S. Y.; Reichl, U.: Engineered defective interfering particles of influenza A virus for antiviral treatment. 33^rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)

Pelz, L.; Rüdiger, D.; Hein, M. D.; Böhme, J.; Bälkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A.; Genzel, Y.; Bruder, D. et al.; Kupke, S. Y.; Reichl, U.: Genetic engineering of Influenza A virus defective interfering particles towards improved antiviral efficacy and potential use as a live vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Rüdiger, D.; Opitz, P.; Kupke, S. Y.; Reichl, U.: A two-dimensional model to predict influenza virus and defective interfering particle coinfection in tissue-like systems. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Rüdiger, D.; Opitz, P.; Kupke, S. Y.; Reichl, U.: Predicting the antiviral efficacy of defective interfering particles against influenza virus infection in tissues. KSMB-SMB 2024, Seoul (South Korea) (2024)

Zinnecker, T. M.; Thiele, K.; Schmidberger, T.; Reichl, U.; Genzel, Y.: Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Zuniga-Banuelos, F. J.; Lemke, G.; Hoffmann, M.; Reichl, U.; Rapp, E.: Discovering Rare Sialylated N glycans Holding O Acetylation or Sulfation within the Site-Specific N glycosylation of Human Serum IgA. SialoGlyco 2024 (International Conference in SialoGlycobiology 2024), Lille (France) (2024)

Zuniga-Banuelos, F. J.; Lemke, G.; Hoffmann, M.; Reichl, U.; Rapp, E.: Including N glycopeptides Bearing Glucuronidated, O Acetylated or Sulfated N glycans in the Analysis of Human Serum Proteins such as Immunoglobulin A. 33rd Joint Glycobiology Meeting (JGM) , Hannover (Germany) (2024)

Zuniga-Banuelos, F. J.; Lemke, G.; Hoffmann, M.; Reichl, U.; Rapp, E.: Expanding Glycoproteomics: Including N‑glycopeptides Bearing Glucuronidated, O‑Acetylated or Sulfated N‑glycans in the Analysis of Human Serum Proteins such as Immunoglobulin A. EGC 2024 webinar (European Glycoscience Community Webinar Series), online (2024)

Alcalá Orozco, E. A.; Huber, N.; Klamt, S.; Rexer, T.; Reichl, U.: A cell-free enzymatic cascade for the synthesis of GDP-fucose - modeling and optimization. GlycoBioTec 2023, Berlin, Germany (2023)

Alcalá Orozco, E. A.; Huber, N.; Klamt, S.; Rexer, T.; Reichl, U.: Development of a cell-free enzymatic cascade for the synthesis of GDP-fucose - modeling and optimization. GlycoBioTec 2023, Berlin, Germany (2023)

Alcalá Orozco, E. A.; Huber, N.; Klamt, S.; Rexer, T.; Reichl, U.: A cell-free enzymatic cascade for the synthesis of GDP-fucose - modeling and optimization. 3^rd Japan-Switzerland-Germany Workshop on Biocatalysis and Bioprocess Development , Aichi (Japan) (2023)

Dogra, T.; Pelz, L.; Boehme, J. D.; Baelkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A. D.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 17^th Vaccine Congress, Glasgow (Scotland) (2023)

Dogra, T.; Pelz, L.; Rüdiger, D.; Kupke, S. Y.; Reichl, U.: Reverse genetics for Influenza a virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination. Vir-AI-DIP Workshop , Hamburg (Germany) (2023)

Genzel, Y.; Zinnecker, T. M.; Göbel, S.; Reichl, U.: Intensified cell-based virus production: A process development challenge for multiple cell-virus combinations. 16^th PEACe Conference, Sitges (Spain) (2023)

Genzel, Y.; Zinnecker, T. M.; Göbel, S.; Reichl, U.: Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus Yield. International Society for Vaccines (ISV) Annual Congress, Lausanne (Switzerland) (2023)

Genzel, Y.; Zinnecker, T. M.; Göbel, S.; Reichl, U.: Increase in supply through use of new technologies for high yield vaccines. Flanders Vaccine, Brussels (Belgium) (2023)

Göbel, S.; Dallmeier, K.; Jordan, I.; de Jong, J.; Reichl, U.; Genzel, Y.: Intensified production for a yellow fever - ZIKA virus vaccine candicate. Democratization of biotherapies: new manufacturing modalities and intensification's, Oxford, UK (2023)

Göbel, S.; Jaén, K. E.; Pelz, L.; Reiter , M.; Altomonte, J.; Reichl, U.; Genzel, Y.: Intensifiying OSB processes for high titer virus production. 5^th large scale meeting: Orbital shaken bioreactors, Girona (Spain) (2023)